Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 41528330.
- Also identified by DOI 10.1158/1078-0432.CCR-25-4251.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutational burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. In this study, we contextualize a recent study evaluating high plasma TMB after targeted therapy and its implications for immunotherapy. See related article by Yeh et al., p. 1100.
Medical subject headings
- Colorectal Neoplasms
- Immunotherapy
- Biomarkers, Tumor